Trials / Terminated
TerminatedNCT01159964
Evaluation of a New Anti-cancer Vaccine for Patients With Non-small Cell Lung Cancer, After Tumor Removal by Surgery
Study of GSK2302032A Antigen-Specific Cancer Immunotherapeutic in Patients With Resectable Non-Small Cell Lung Cancer
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 60 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this clinical study is to assess the safety and immunogenicity of the immunotherapeutic product GSK 2302032A when given to Non-Small Cell Lung Cancer (NSCLC) patients, after tumor removal by surgery.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Immunotherapeutic GSK2302032A, different formulations | Intramuscular administration |
Timeline
- Start date
- 2010-07-20
- Primary completion
- 2011-10-19
- Completion
- 2014-09-10
- First posted
- 2010-07-12
- Last updated
- 2018-06-18
Locations
37 sites across 6 countries: United States, France, Germany, Italy, Poland, Russia
Source: ClinicalTrials.gov record NCT01159964. Inclusion in this directory is not an endorsement.